Ivermectin B1b
CAT:
804-HY-125729
Size:
500 µg
For Laboratory Research Only. Not for Clinical or Personal Use.
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Ivermectin B1b
UNSPSC Description:
Ivermectin B1b is the minor component of Ivermectin. Ivermectin, a potent anti-parasitic agent, inhibits the replication of SARS-CoV-2 in cell culture[1][2].Target Antigen:
Parasite; SARS-CoVType:
Natural ProductsRelated Pathways:
Anti-infectionApplications:
COVID-19-anti-virusField of Research:
InfectionAssay Protocol:
https://www.medchemexpress.com/ivermectin-b1b.htmlPurity:
98.66Solubility:
DMSO : 50 mg/mL (ultrasonic)Smiles:
CC([C@H]1O[C@]2(CC[C@@H]1C)C[C@](O3)([H])C[C@](C/C=C([C@H]([C@H](/C=C/C=C4[C@@]5(O)[C@](C=C(C)[C@@H](O)[C@@]5([H])OC/4)([H])C3=O)C)O[C@@]6([H])C[C@@H]([C@@H](O[C@@]7([H])C[C@@H]([C@@H](O)[C@H](C)O7)OC)[C@H](C)O6)OC)\C)([H])O2)CMolecular Weight:
861.07References & Citations:
[1]Katz N, et al. Ivermectin efficacy against Biomphalaria, intermediate host snail vectors of Schistosomiasis. J Antibiot (Tokyo). 2017;70(5):680-684.|[2]Bray M, et al. Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses. Antiviral Res. 2020;178:104805.|[3]Demeler J, et al. Measuring the effect of avermectins and milbemycins on somatic muscle contraction of adult Haemonchus contortus and on motility of Ostertagia circumcincta in vitro. Parasitology. 2014;141(7):948-956.|[4]Collins T, et al. Nicotinic acetylcholine receptor transmembrane mutations convert ivermectin from a positive to a negative allosteric modulator. Mol Pharmacol. 2010;78(2):198-204.Shipping Conditions:
Blue IceStorage Conditions:
-20°C, 3 years (Powder)Clinical Information:
No Development ReportedCAS Number:
70209-81-3
